FGP
CNMD icon

Freestone Grove Partners’s CONMED CNMD Stock Holding History

Freestone Grove Partners’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Buy
8,336
+7,309
+712% +$263K ﹤0.01% 774
2026
Q1 		$36.3K Sell
1,027
-10,190
-91% -$415K ﹤0.01% 847
2025
Q4 		$455K Buy
+11,217
New +$488K ﹤0.01% 587

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Freestone Grove Partners's CNMD Position: Q2 2026 in Review

Freestone Grove Partners increased its CONMED (CNMD) stake by 712% in Q2 2026, buying an estimated $263K and bringing the position to 8,336 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #774.

Freestone Grove Partners first reported a position in CNMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $455K in Q4 2025. 247 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • Freestone Grove Partners held 8,336 shares of CONMED worth $273K as of Q2 2026.
  • Freestone Grove Partners bought 7,309 CONMED shares in Q2 2026, an estimated $263K.
  • CONMED made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #774 holding.
  • Freestone Grove Partners first reported a position in CONMED in Q4 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's CONMED position peaked at $455K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.